Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin‐based chemotherapy

Abstract

Abbreviations & AcronymsObjectives: To create a novel prognostic model to predict survival in metastatic upper tract urothelial carcinoma patients treated with cisplatin-based chemotherapy. Methods: After institutional review board approval, patients who had metastatic upper tract urothelial carcinoma and were treated with cisplatin based chemotherapy from 2000 to 2012 at Kaohsiung Chang Gung Memorial Hospital were retrospectively reviewed. Significantly predictive factors were identified by multivariate Cox regress analyses. Kaplan-Meier curves were plotted to estimate overall survival. Several prognostic models were validated by using our cohort, and Harrell's c-index was calculated to evaluate their predicting performances.Results: The present study consisted of 136 patients with a median age of 62 years and a median follow-up visit of 13.6 months. Multivariate analyses showed that renal function, performance status, liver metastasis and number of metastatic sites was independently related to survival. Based on these four variables, we constructed a prognostic model "renal function, performance status, liver metastasis, number of metastatic sites" with significantly different survival (P < 0. Conclusions: Our renal function, performance status, liver metastasis, number of metastatic sites prognostic model could be useful for providing prognostic information on survival in patients with metastatic upper tract urothelial carcinoma.

Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma

“… 16 Hsieh et al reported that cisplatin‐fit renal function (CrCl > 60 mL/min) was an independently good prognostic factor for metastatic UTUC patients treated with cisplatin‐based chemotherapy (MVAC; N = 63, GC; N = 73). 17 The dose reduction protocol for the cisplatin‐based regimen was not clarified in this study either. Compared with previous reports, our cohort study was organized by a single GC regimen under unified protocol of reduced cisplatin with more metastatic UC patients.…”

“…This retrospective study consists of different types of regimens which include only three cases of MVAC and GC in the reduced dose group 16 . Hsieh et al reported that cisplatin‐fit renal function (CrCl > 60 mL/min) was an independently good prognostic factor for metastatic UTUC patients treated with cisplatin‐based chemotherapy (MVAC; N = 63, GC; N = 73) 17 . The dose reduction protocol for the cisplatin‐based regimen was not clarified in this study either.…”